Objectives: We evaluated whether tibolone had an adverse effect on the progression free survival and overall survival of epithelial ovarian cancer patients.
Methods: Forty-two tibolone users and 33 non-users who had been surgically managed for epithelial ovarian cancer at Gil Medical Center, Inchon, Korea, from January 1997 to December 2003 were reviewed retrospectively.
Results: There were no statistically significant differences in age, stage, histology, grade and surgical optimality between tibolone users and non-users. The progression free survival at 36 months was 60.0% among the users compared with 61.5% among the non-users (p=0.92). There was also no significant difference in the overall survival between two groups (p=0.30). For stage IIIc patients according to tibolone using, there were no significant differences in the progression free survival (p=0.86) and overall survival (p=0.36) between tibolone users and non-users.
Conclusions: There was no evidence that tibolone had detrimental effects on the progression free survival and overall survival of epithelial ovarian cancer patients. So, tibolone could be used in these patients.